Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Days Payable Chart
SHSE:688513 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Days Payable falls into.
Chengdu Easton Biopharmaceuticals Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Days Payable of 142.54 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 16% below median its historical median of 169.75. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Days Payable has ranged from 61.13 to 415.97. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #313 out of 701 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Chengdu Easton Biopharmaceuticals Co's Days Payable too high?
Chengdu Easton Biopharmaceuticals Co's current Days Payable of 142.54 is 16% below median its 10-year median of 169.75. Over the past 10 years, this metric has ranged from a low of 61.13 to a high of 415.97. The Biotechnology industry median Days Payable is 112.84. Chengdu Easton Biopharmaceuticals Co's value of 142.54 is 26.3% above this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #313 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #313 out of 701 companies for Days Payable. This puts Chengdu Easton Biopharmaceuticals Co in the upper half of its industry. The industry median Days Payable is 112.84. Chengdu Easton Biopharmaceuticals Co's value of 142.54 is 26.3% above this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own Days Payable has ranged from 61.13 to 415.97 over the past decade. While the company's 10-year median is 169.75 vs. the industry median of 112.84, Chengdu Easton Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current Days Payable of 142.54 is 26.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current Days Payable is 142.54, which is 16% below median its own 10-year median of 169.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥48.04, compared to a current price of ¥57.55 — trading 19.8% above its estimated fair value. The current Days Payable is 142.54, which is 16% below median its 10-year median of 169.75 and 26.3% above the Biotechnology industry median of 112.84. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Days Payable is 142.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥57.55 is trading 19.8% above its estimated GF Value™ of ¥48.04.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SHSE:688513:
Days Payable: 142.54 (16% below median its 10-year median of 169.75)
GF Value™: ¥48.04 vs. price of ¥57.55 (19.8% above fair value)
Industry Position: 26.3% above the Biotechnology median (#313 of 701)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
94GF Score
Get the complete analysis for SHSE:688513
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
